Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 89417 | 3.82 |
09:34 ET | 58192 | 3.78 |
09:36 ET | 18996 | 3.815 |
09:38 ET | 15875 | 3.8428 |
09:39 ET | 8004 | 3.85 |
09:41 ET | 14167 | 3.84 |
09:43 ET | 16050 | 3.83 |
09:45 ET | 9800 | 3.84 |
09:48 ET | 13029 | 3.83 |
09:50 ET | 13257 | 3.83 |
09:52 ET | 7423 | 3.815 |
09:54 ET | 63668 | 3.81 |
09:56 ET | 5867 | 3.83 |
09:57 ET | 81779 | 3.82 |
09:59 ET | 22787 | 3.83 |
10:01 ET | 13627 | 3.82 |
10:03 ET | 18163 | 3.82 |
10:06 ET | 4321 | 3.82 |
10:08 ET | 22353 | 3.8 |
10:10 ET | 9508 | 3.82 |
10:12 ET | 2600 | 3.82 |
10:14 ET | 23020 | 3.835 |
10:15 ET | 16770 | 3.815 |
10:17 ET | 15293 | 3.83 |
10:19 ET | 13350 | 3.835 |
10:21 ET | 35825 | 3.84 |
10:24 ET | 42958 | 3.875 |
10:26 ET | 31982 | 3.88 |
10:28 ET | 11837 | 3.885 |
10:30 ET | 38351 | 3.88 |
10:32 ET | 8749 | 3.8802 |
10:33 ET | 5499 | 3.875 |
10:35 ET | 8537 | 3.88 |
10:37 ET | 8532 | 3.87 |
10:39 ET | 9128 | 3.865 |
10:42 ET | 13774 | 3.87 |
10:44 ET | 14180 | 3.8897 |
10:46 ET | 5853 | 3.88 |
10:48 ET | 5438 | 3.885 |
10:50 ET | 24879 | 3.88 |
10:51 ET | 10998 | 3.8675 |
10:53 ET | 2491 | 3.865 |
10:55 ET | 3626 | 3.865 |
10:57 ET | 5124 | 3.865 |
11:00 ET | 4055 | 3.86 |
11:02 ET | 28283 | 3.87 |
11:04 ET | 19265 | 3.87 |
11:06 ET | 4805 | 3.875 |
11:08 ET | 7136 | 3.885 |
11:09 ET | 7928 | 3.885 |
11:11 ET | 4945 | 3.885 |
11:13 ET | 2532 | 3.89 |
11:15 ET | 25773 | 3.89 |
11:18 ET | 910 | 3.885 |
11:20 ET | 31490 | 3.885 |
11:22 ET | 13408 | 3.875 |
11:24 ET | 10392 | 3.865 |
11:26 ET | 10581 | 3.87 |
11:27 ET | 2919 | 3.865 |
11:29 ET | 7622 | 3.855 |
11:31 ET | 5845 | 3.855 |
11:33 ET | 7319 | 3.86 |
11:36 ET | 3480 | 3.85 |
11:38 ET | 5667 | 3.855 |
11:40 ET | 2253 | 3.8515 |
11:42 ET | 4535 | 3.86 |
11:44 ET | 17454 | 3.85 |
11:45 ET | 1770 | 3.85 |
11:47 ET | 77181 | 3.875 |
11:49 ET | 3576 | 3.875 |
11:51 ET | 30702 | 3.86 |
11:54 ET | 4008 | 3.845 |
11:56 ET | 1660 | 3.84 |
11:58 ET | 3197 | 3.835 |
12:00 ET | 6672 | 3.835 |
12:02 ET | 15905 | 3.845 |
12:03 ET | 1336 | 3.84 |
12:05 ET | 3975 | 3.84 |
12:07 ET | 2945 | 3.845 |
12:09 ET | 15841 | 3.835 |
12:12 ET | 6027 | 3.835 |
12:14 ET | 4486 | 3.835 |
12:16 ET | 8237 | 3.8203 |
12:18 ET | 1835 | 3.825 |
12:20 ET | 17214 | 3.815 |
12:21 ET | 13323 | 3.8287 |
12:23 ET | 5061 | 3.825 |
12:25 ET | 6672 | 3.83 |
12:27 ET | 7150 | 3.825 |
12:30 ET | 2650 | 3.825 |
12:32 ET | 3300 | 3.825 |
12:34 ET | 14157 | 3.825 |
12:36 ET | 7010 | 3.825 |
12:38 ET | 9297 | 3.81 |
12:39 ET | 8821 | 3.815 |
12:41 ET | 19118 | 3.825 |
12:43 ET | 8554 | 3.8399 |
12:45 ET | 2457 | 3.835 |
12:48 ET | 4416 | 3.83 |
12:50 ET | 10208 | 3.825 |
12:52 ET | 14533 | 3.815 |
12:54 ET | 2391 | 3.815 |
12:56 ET | 4600 | 3.815 |
12:57 ET | 6056 | 3.815 |
12:59 ET | 19982 | 3.805 |
01:01 ET | 20904 | 3.805 |
01:03 ET | 401 | 3.8 |
01:06 ET | 2500 | 3.805 |
01:08 ET | 3987 | 3.805 |
01:10 ET | 5827 | 3.805 |
01:12 ET | 6800 | 3.805 |
01:14 ET | 6955 | 3.8 |
01:15 ET | 37240 | 3.815 |
01:17 ET | 1546 | 3.82 |
01:19 ET | 6773 | 3.81 |
01:21 ET | 16499 | 3.8 |
01:24 ET | 12816 | 3.8 |
01:26 ET | 13070 | 3.805 |
01:28 ET | 2322 | 3.805 |
01:30 ET | 2880 | 3.805 |
01:32 ET | 6900 | 3.805 |
01:33 ET | 34824 | 3.815 |
01:35 ET | 11300 | 3.8 |
01:37 ET | 42700 | 3.805 |
01:39 ET | 3300 | 3.8 |
01:42 ET | 4395 | 3.8 |
01:44 ET | 53493 | 3.81 |
01:46 ET | 1700 | 3.805 |
01:48 ET | 6890 | 3.805 |
01:50 ET | 5607 | 3.81 |
01:51 ET | 7800 | 3.8 |
01:53 ET | 10716 | 3.81 |
01:55 ET | 2410 | 3.805 |
01:57 ET | 14297 | 3.805 |
02:00 ET | 12600 | 3.805 |
02:02 ET | 4419 | 3.805 |
02:04 ET | 2108 | 3.805 |
02:06 ET | 7082 | 3.805 |
02:08 ET | 11605 | 3.805 |
02:09 ET | 4300 | 3.8 |
02:11 ET | 24259 | 3.815 |
02:13 ET | 4362 | 3.815 |
02:15 ET | 4068 | 3.815 |
02:18 ET | 7345 | 3.815 |
02:20 ET | 5836 | 3.81 |
02:22 ET | 1600 | 3.815 |
02:24 ET | 6086 | 3.815 |
02:26 ET | 3078 | 3.815 |
02:27 ET | 29043 | 3.825 |
02:29 ET | 3066 | 3.82 |
02:31 ET | 19568 | 3.835 |
02:33 ET | 14627 | 3.845 |
02:36 ET | 3471 | 3.845 |
02:38 ET | 13445 | 3.845 |
02:40 ET | 1481 | 3.845 |
02:42 ET | 8396 | 3.84 |
02:44 ET | 3428 | 3.845 |
02:45 ET | 3263 | 3.845 |
02:47 ET | 2063 | 3.845 |
02:49 ET | 1084 | 3.845 |
02:51 ET | 2971 | 3.84 |
02:54 ET | 3975 | 3.845 |
02:56 ET | 4294 | 3.845 |
02:58 ET | 8351 | 3.845 |
03:00 ET | 47920 | 3.83 |
03:02 ET | 15632 | 3.8399 |
03:03 ET | 21579 | 3.82 |
03:05 ET | 21296 | 3.8 |
03:07 ET | 10681 | 3.805 |
03:09 ET | 12090 | 3.8 |
03:12 ET | 53906 | 3.8 |
03:14 ET | 28229 | 3.8 |
03:16 ET | 32428 | 3.805 |
03:18 ET | 22876 | 3.815 |
03:20 ET | 7575 | 3.82 |
03:21 ET | 17615 | 3.825 |
03:23 ET | 26179 | 3.83 |
03:25 ET | 5564 | 3.83 |
03:27 ET | 4361 | 3.825 |
03:30 ET | 3428 | 3.825 |
03:32 ET | 3842 | 3.825 |
03:34 ET | 6523 | 3.825 |
03:36 ET | 50801 | 3.82 |
03:38 ET | 25577 | 3.815 |
03:39 ET | 19999 | 3.815 |
03:41 ET | 7598 | 3.815 |
03:43 ET | 6982 | 3.815 |
03:45 ET | 18397 | 3.81 |
03:48 ET | 15741 | 3.815 |
03:50 ET | 20597 | 3.815 |
03:52 ET | 307339 | 3.83 |
03:54 ET | 142625 | 3.83 |
03:56 ET | 195860 | 3.805 |
03:57 ET | 28394 | 3.805 |
03:59 ET | 3131016 | 3.81 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.3B | -11.0x | --- |
CG Oncology Inc | 2.3B | -30.4x | --- |
Dyne Therapeutics Inc | 2.2B | -6.5x | --- |
Sana Biotechnology Inc | 2.2B | -6.5x | --- |
Vera Therapeutics Inc | 2.5B | -19.7x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -8.0x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.45 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.0x |
Price/Sales (TTM) | 4,345.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.